$917 Million is the total value of Euclidean Capital LLC's 25 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GLD | Buy | SPDR GOLD TR | $364,331,250 | +268.2% | 2,125,000 | +282.9% | 39.75% | +56.4% |
| INDA | Buy | ISHARES TRmsci india etf | $214,479,736 | +102.4% | 4,850,288 | +100.0% | 23.40% | -14.1% |
| SPY | Buy | SPDR S&P 500 ETF TRtr unit | $210,533,900 | +92.9% | 492,500 | +100.0% | 22.97% | -18.1% |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $32,267,456 | +102.5% | 5,255,286 | +106.5% | 3.52% | -14.0% |
| RAPT | Buy | RAPT THERAPEUTICS INC | $21,868,562 | +104.7% | 1,315,798 | +130.3% | 2.39% | -13.1% |
| ME | Buy | 23ANDME HOLDING CO | $20,029,400 | +11.7% | 20,486,244 | +100.0% | 2.18% | -52.6% |
| ALEC | Buy | ALECTOR INC | $16,949,840 | +187.5% | 2,615,716 | +166.7% | 1.85% | +22.0% |
| FHTX | Buy | FOGHORN THERAPEUTICS INC | $15,737,610 | +42.0% | 3,147,522 | +100.0% | 1.72% | -39.7% |
| ORIC | Buy | ORIC PHARMACEUTICALS INC | $11,971,862 | +106.4% | 1,978,820 | +164.7% | 1.31% | -12.4% |
| Buy | TENAYA THERAPEUTICS INC | $5,180,096 | -3.6% | 2,031,410 | +121.8% | 0.56% | -59.1% | |
| NGM | Buy | NGM BIOPHARMACEUTICALS INC | $2,123,240 | +9.8% | 1,984,336 | +165.8% | 0.23% | -53.3% |
| Buy | SURROZEN INC | $1,038,029 | +135.0% | 2,118,426 | +163.8% | 0.11% | 0.0% | |
| New | SURROZEN INC*w exp 08/01/203 | $7,021 | – | 170,833 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
| FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
| NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
| ALECTOR INC | 12 | Q3 2023 | 11.5% |
| RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
| TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
| FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
| SURROZEN INC | 9 | Q3 2023 | 2.9% |
| 23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2023-12-01 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.